FDA provides conditional approval of next generation driver for Sunshine Heart’s novel cardiac device
Sunshine Heart (NASDAQ Capital Markets: SSH), which makes a an implantable, non-blood contacting, cardiac assist device to treat moderate to severe heart failure, has received conditional approval from the U.S. Food and Drug Administration for a component of that device. The public company, which has been the recipient of a huge amount of interest from investors […]